We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis DTC Email for OA Drug Has Unequal Risk-Benefit Ratio
Novartis DTC Email for OA Drug Has Unequal Risk-Benefit Ratio
April 23, 2010
The FDA has issued an untitled letter to Novartis for a direct-to-consumer (DTC) email on its osteoarthritis drug Voltaren Gel because the email minimizes risks, broadens the indication and overstates the drug’s efficacy.